TABLE 3.
Association of HLA class I alleles with CD8+ CTL response to ALVAC-HIV canarypox vaccinea
| Allele consistently associated with altered HIV disease progressionb | HIV protein | 6 wksc
|
26 wksd
|
2.5 yrse
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. (%) of persons with CTL response
|
ORf | No. (%) of persons with CTL response
|
ORf | No. (%) of persons with CTL response
|
ORf | |||||
| With allele | Without allele | With allele | Without allele | With allele | Without allele | |||||
| B∗08 (F) | Any | 9 (16) | 27 (12) | 1.3 | 2 (3) | 29 (13) | 0.2g | 15 (25) | 60 (27) | 0.9 |
| Gag | 4 (13) | 20 (21) | 0.6 | 0 (0) | 23 (16) | 0.0h | 8 (15) | 51 (25) | 0.5 | |
| Env | 6 (19) | 11 (11) | 1.9 | 2 (6) | 13 (9) | 0.6 | 7 (13) | 28 (14) | 0.9 | |
| B∗27 (S) | Any | 8 (40) | 28 (11) | 5.4i | 8 (35) | 23 (9) | 5.5i | 14 (61) | 61 (23) | 5.2i |
| Gag | 7 (64) | 17 (15) | 10.3i | 6 (33) | 17 (10) | 4.4g | 12 (55) | 47 (20) | 4.9i | |
| Env | 4 (36) | 13 (11) | 4.6g | 3 (18) | 12 (8) | 2.6 | 4 (18) | 31 (13) | 1.5 | |
| B∗35 (F) | Any | 3 (9) | 33 (14) | 0.6 | 4 (11) | 27 (11) | 1.1 | 8 (22) | 67 (27) | 0.8 |
| Gag | 2 (13) | 22 (19) | 0.6 | 3 (14) | 20 (12) | 1.2 | 6 (18) | 53 (23) | 0.7 | |
| Env | 1 (7) | 16 (14) | 0.4 | 1 (5) | 14 (9) | 0.5 | 3 (9) | 32 (14) | 0.6 | |
| B∗57 (S) | Any | 4 (21) | 32 (12) | 1.9 | 5 (26) | 26 (10) | 3.3g | 7 (37) | 68 (25) | 1.7 |
| Gag | 2 (20) | 22 (19) | 1.1 | 5 (39) | 18 (11) | 5.3g | 7 (39) | 52 (21) | 2.3 | |
| Env | 4 (44) | 13 (11) | 6.6g | 5 (39) | 10 (6) | 9.5i | 7 (41) | 28 (12) | 5.3i | |
Cumulative responses: one positive CTL measurement by 2 weeks after second dose and two positive CTL measurements by 2 weeks after third or fourth dose and by 1.5 years after third through sixth doses. The numbers of subjects with typing and CTL measurements varied by protocol and interval.
References 8, 11, 21, 22, 25, 26, 28, 29, 35, 38, 40, and 50. Previous association with progression: F, faster; S, slower.
Two weeks after second dose.
Two weeks after third or fourth dose (postvaccination interval relative to third or fourth dose in protocols 022, 022A, and 026 and relative to fourth dose in protocol 029; see Table 1 and the text).
Two to 78 weeks after third through sixth doses.
Associations remain comparably significant when subjects carrying additional alleles associated with increased CTL are excluded from analysis and whether subjects in protocol 029 are included in the analysis of response 2 weeks after the second dose.
P < 0.05.
P < 0.01.
P < 0.05.